Takayuki Tsujioka
Overview
Explore the profile of Takayuki Tsujioka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hazama Y, Tsujioka T, Kitanaka A, Tohyama K, Shimoya K
PLoS One
. 2022 Jul;
17(7):e0271245.
PMID: 35802681
The prognosis of the patients with inoperable or advanced granulosa cell tumors (GCTs) is still poor, and therefore it is important to establish a novel treatment strategy. Here we investigated...
2.
Kurozumi N, Tsujioka T, Ouchida M, Sakakibara K, Nakahara T, Suemori S, et al.
Cancer Sci
. 2021 May;
112(8):3302-3313.
PMID: 34032336
A novel proteasome deubiquitinase inhibitor, VLX1570, has been highlighted as a promising therapeutic agent mainly for lymphoid neoplasms and solid tumors. We examined in vitro effects of VLX1570 on eight...
3.
Sakakibara K, Tsujioka T, Kida J, Kurozumi N, Nakahara T, Suemori S, et al.
Int J Hematol
. 2019 May;
110(2):213-227.
PMID: 31129802
A MEK1/2 inhibitor, binimetinib is promising as a therapeutic agent for malignant melanoma with N-RAS mutation. We examined in vitro effects of binimetinib on 10 human myeloid/lymphoid leukemia cell lines,...
4.
Kida J, Tsujioka T, Suemori S, Okamoto S, Sakakibara K, Takahata T, et al.
Leukemia
. 2018 Jun;
32(8):1846-1850.
PMID: 29955132
No abstract available.
5.
Nakahara T, Suemori S, Tsujioka T, Kataoka M, Kataoka H, Shibakura M, et al.
Acta Med Okayama
. 2018 Jun;
72(3):249-256.
PMID: 29926002
To investigate megakaryocyte (MK) DNA ploidy in various hematological diseases, fluorescence microscopy imaging system (FMI) can be used to analyze DNA ploidy with cell morphology at the single-cell level by...
6.
Kondo T, Tasaka T, Tomioka N, Sano F, Tokunaga H, Suemori S, et al.
Springerplus
. 2016 Aug;
5(1):1146.
PMID: 27504244
Calreticulin (CALR) and JAK2-V617F gene mutations, which are major genetic mutations in patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET), exert different effects on the clinical features and outcomes...
7.
Okamoto S, Tsujioka T, Suemori S, Kida J, Kondo T, Tohyama Y, et al.
Cancer Sci
. 2016 Jun;
107(9):1302-14.
PMID: 27311589
Treatment outcomes for acute myeloid leukemia and myelodysplastic syndromes (MDS) remain unsatisfactory despite progress in various types of chemotherapy and hematopoietic stem cell transplantation. Therefore, there is a need for...
8.
Tsujioka T, Yokoi A, Itano Y, Takahashi K, Ouchida M, Okamoto S, et al.
Sci Rep
. 2015 Nov;
5:16709.
PMID: 26577244
DNA methyltransferase inhibitors (DNMT inhibitors) are administered for high-risk MDS, but their action mechanisms are not fully understood. Hence, we performed a genome-wide DNA methylation assay and focused on cholesterol...
9.
Analysis of Hereditary Elliptocytosis with Decreased Binding of Eosin-5-maleimide to Red Blood Cells
Suemori S, Wada H, Nakanishi H, Tsujioka T, Sugihara T, Tohyama K
Biomed Res Int
. 2015 Nov;
2015:451861.
PMID: 26557672
Flow cytometric test for analyzing the eosin-5-maleimide (EMA) binding to red blood cells has been believed to be a specific method for diagnosing hereditary spherocytosis (HS). However, it has been...
10.
Hyoda T, Tsujioka T, Nakahara T, Suemori S, Okamoto S, Kataoka M, et al.
Cancer Sci
. 2015 Jan;
106(3):287-93.
PMID: 25580850
A multi-kinase inhibitor, rigosertib (ON 01910.Na) has recently been highlighted as a novel type of anti-cancer agent for the treatment of the myelodysplastic syndromes (MDS), but its action mechanisms remain...